On behalf of the entire team, I would first and foremost like to thank you for the trust you haveplaced in us. In 2015, thanks to the substantial funds raised at the start of the year, we were able to consolidate and accelerate our positioning in France, the United States and the rest of the world. We transformed the JAZZ implant into a comprehensive range of implants, the JAZZ Band™, providing a response to all the demands expressed by spine surgeons. We have made remarkable progress on this market, as illustrated by the sales recorded by our American subsidiary, reflecting the extent of the new and substantial medical value we provide through our innovative products.
Following the recent regulatory approval received to market JAZZ in Brazil and the FDA clearance granted to use JAZZ for all fixation systems available on the market, in October we surpassed 10,000 JAZZ implants sold, a highly-symbolic figure that today illustrates the merits of our development strategy. We are constantly intensifying our efforts on our main markets to promote our technology within the scientific and medical communities. We have laid the key foundations for our global growth through a firmly-established organization that we are improving day after day, a dedicated 25-agency sales network in the United States, distributors in more than 15 countries, a Board of Directors consisting of leading experts in the field of spine surgery, as well as first-rate medical advisers.
Despite the difficult financial market context, we are today perfectly positioned to continue our growth momentum in 2016, which we believe will be an excellent year for us. More than ever, we are preparing to become a global company: we are proud to be able to count on you to accompany our growth, and hence to enable people suffering from serious spine disorders to benefit from our unrivalled medical innovation.
Chief Executive Officer